References
- McCormack AI, Dekkers O, Petersenn S, et al. Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. Eur J Endocrinol. 2018 Jan 12. pii: EJE-17-0933. doi:10.1530/EJE-17-0933. [ Epub ahead of print] PMID:29330228
- Chanal M, Chevallier P, Raverot V, et al. Differential effect of PI3K and dual PI3K/mTOR inhibition in rat prolactin-secreting pituitary tumors. Mol Cancer Ther. 2016;15:1261–1270. doi:10.1158/1535-7163.MCT-15-0891. PMID:26983879
- Fedele M, Battista S, Kenyon L, et al. Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene. 2002;21:3190–3198. doi:10.1038/sj.onc.1205428. PMID:12082634
- Sotillo R, Renner O, Dubus P, et al. Cooperation between Cdk4 and p27kip1 in tumor development: a preclinical model to evaluate cell cycle inhibitors with therapeutic activity. Cancer Res. 2005;65:3846–3852. doi:10.1158/0008-5472.CAN-04-4195. PMID:15867383
- Fedele M, Paciello O, De Biase D, et al. HMGA2 cooperates with either p27kip1 deficiency or Cdk4R24C mutation in pituitary tumorigenesis. Cell cycle. 2017;16(15):1430–1439. PMID:28723239
- Raverot G, Jouanneau E, Trouillas J. Management of endocrine disease: clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies. Eur J Endocrinol. 2014 Mar 13;170(4):R121–32. Print 2014 Apr. Review. doi:10.1530/EJE-13-1031.
- Asa SL, Casar-Borota O, Chanson P, et al. From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. Endocr Relat Cancer. 2017;24(4):C5–C8. doi:10.1530/ERC-17-0004. PMID:28264912